Menu
Not yet recruiting NCT07059910

Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment

Observational Immune Thrombocytopenic Purpura Thyroid Disorders

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Search for thyroid disorders, Laboratory test, Steroid and eltrombopage.
Who it may be relevant to
Registry conditions: Immune Thrombocytopenic Purpura, Thyroid Disorders. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment

Detailed description

We investigate patients with ITP for screening of thyroid disorders and how to deal with it and effect of this on the ttt

Interventions

  • Diagnostic test Search for thyroid disorders
    TSH , FT3 , FT4
  • Diagnostic test Laboratory test
    Search for anti thyroid antibodies
  • Drug Steroid and eltrombopage
    See when we treat thyroid disorders, will patient respond to steroid or eltrombopage?

Primary outcome measures

  • Assess the frequency of thyroid disorders in patients with IT [Time frame: Assess the frequency of thyroid disorders in patients with IT]
  • Evaluate the treatment of thyroid disorders in improvement in platelets count. [Time frame: Evaluate the treatment of thyroid disorders in improvement in platelets count.]

Eligibility criteria

Inclusion criteria

  • ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively.
  • refractory ITP patients.

Exclusion criteria

  • patients with history of thyroidectomy
  • patients with history of drug induced ITP
  • patients with history of HCV, HBV and HIV infection.
  • Patients who refuse to contribute in this study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07059910 · ITP and thyroid disorders

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗